Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1Phase 2 1Phase 1 1

Status

Recruiting 3Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Sarcoma 1Other solid neoplasm 1Other hematologic neoplasm 1Gynecologic 1Gastrointestinal 1

Conditions

Rectal Neoplasms 1Ovarian Carcinosarcoma 1Noonan Syndrome 5 1Neoplasms 1Hematologic Neoplasms 1Cardiovascular Diseases 1Advanced Solid Tumor 1

Interventions

Specimen Handling 454Magnetic Resonance Spectroscopy 347pembrolizumab 289Biopsy 244Carboplatin 230Cisplatin 194Cyclophosphamide 186Paclitaxel 164Nivolumab 154Gemcitabine 151Radiotherapy 125Bevacizumab 124Dexamethasone 113fludarabine 100Pemetrexed 99Fluorouracil 94Doxorubicin 92durvalumab 91Radiation 91Docetaxel 91venetoclax 89Rituximab 88Oxaliplatin 88atezolizumab 87Leucovorin 79Capecitabine 76Prednisone 75Lenalidomide 70Etoposide 69X-Rays 66

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Antineoplastic Agents × 30 days × Clear all
NCT07621289 2026-06-02

EUCARTOXSCORES

University Hospital, Caen

Not yet recruiting
10,000 enrolled
Other hematologic neoplasm

Cardiovascular Diseases, Neoplasms, Hematologic Neoplasms

NCT03651206 2026-06-01

ROCSAN

ARCAGY/ GINECO GROUP

Phase 2/3 Recruiting
138 enrolled
GynecologicSarcoma

Ovarian Carcinosarcoma

NCT06625593 2026-05-29

A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors

BeOne Medicines

Phase 1 Recruiting
168 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT07594925 2026-05-19

Short-Course Radiotherapy Followed by Immunotherapy Combined With Chemotherapy for Microsatellite Stable Locally Advanced Rectal Cancer: A Prospective, Randomized, Controlled Phase II Clinical Trial

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Recruiting
130 enrolled
Gastrointestinal

Rectal Neoplasms

NCT05566795 2026-05-14

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

Day One Biopharmaceuticals, Inc.

Phase 3 Active not recruiting
418 enrolled

Noonan Syndrome 5

Data powered by HemOnc (CC BY 4.0) Colophon âš¡